RVMD Revolution Medicines, Inc.

NASDAQ
$204.97

Revolution Medicines, Inc. (RVMD) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $2.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.7% since its last earnings release on August 5, 2026.

Revolution Medicines Missed Consensus Estimates
Wednesday, August 5, 2026 · 4:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($2.30)
Rev est $30.72M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $205.06

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers.

Sector

Healthcare

Industry

Biotechnology

Held By 6 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.